Every August, Teva Magyarországon participates in the traditional Debrecen Flower Carnival in Hungary. This year, Teva's beautiful flower composition reflected the message of a national campaign led by Teva to teach a 5-step resuscitation method that can help save lives. “Te vagy a hős!” (You can be a hero!)
Teva Spain shares insights on growing customer loyalty in the pharmacy business, in their latest “Teva Management Academy” feature (in Spanish): Fidelización de Clientes
Congratulations to Dr. Michael Hayden, President of Global R&D and Teva’s Chief Scientific Officer, on being recognized as one of Pharma's 100 Most #Inspiring People! http://viewer.zmags.com/publication/8964fa39#/8964fa39/36
Colleagues at Teva’s Respiratory facility in Waterford, Ireland participated in a week-long challenge to be physically active at least one hour a day for 5 days. Employees collected sponsorships that raised over €2,500 for the Asthma Society and the Cystic Fibrosis ward in the local hospital. The week ended with a fun family fitness event that celebrated the importance of a healthy lifestyle, and Teva’s continued commitment to improving health.
This is the official Google+ page for Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com
Note to Users: This page is intended to provide news and updates about our company, and Teva reserves the right to delete any comments that it considers to be inappropriate, abusive or spam.
Adverse events for any of our products should be reported to: Safety.AE@teva.co.il
Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details may be found here: http://www.tevapharm.com/en-US/Pages/Contact-Us.aspx